Five MASLD subtypes linked to distinct health risks in reported study

ScienceAlert describes a Mayo Clinic-led study that used computational modeling to identify groups of patients with shared characteristics. The analysis considered sex, body mass index, blood markers of liver damage and related conditions, including high blood pressure, obesity and high cholesterol.

The researchers followed patients for up to 10 years and reported different risks of heart disease, liver failure, cancer and liver transplantation across the groups. C1, comprising around 30 percent of participants, included older patients without obesity and had relatively high rates of liver cancer and transplantation. C5 accounted for about 9 percent; the researchers linked genetics to both MASLD susceptibility and complication risk in this group.

The article describes MASLD as a single disease category that the researchers propose subdividing. It does not provide a before-and-after comparison of clinical care using the proposed classification.

The proposed classification separates MASLD into groups designated C1 to C5, with distinct clinical and genetic characteristics. The reported finding is an association between these groups and different longer-term health risks—not evidence that assigning patients to a subtype improves treatment outcomes.

The findings suggest that one diagnosis may encompass patients with meaningfully different disease patterns. That could inform research into more tailored care, but the study does not establish which treatments work best for each group or demonstrate improved outcomes from using the classification.